- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | EMA grants orphan drug designation to AlloVir's Viralym-M | ||
| Fr | FDA approves Bristol Myers Squibb's ZEPOSIA oral treatment for relapsing forms of multiple sclerosis | ||
| Fr | Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease | ||
| Do | Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer | ||
| Do | Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran) | ||
| Do | Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19 | ||
| Mi | AveXis' Zolgensma gene therapy yields desired results in SMA trials | ||
| Di | Hoth Therapeutics announces agreement to joint development for a self-assembling vaccine (SAV) for the potential prevention of coronavirus | ||
| Di | AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML | ||
| Di | FDA approves COVACTA trial for RA drug Actemra in COVID-19 patients | ||
| Mo | ViiV Healthcare secures Canadian approval for HIV drug regimen CABENUVA | ||
| Mo | Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders | ||
| Mo | Amneal accelerates distribution and production of Hydroxychloroquine Sulfate to meet potential needs of COVID-19 patients nationwide | ||
| Mo | Feinstein Institutes begins three clinical trials for COVID-19 patients | ||
| 20.03. | Novartis receives Japanese approval for Zolgensma in spinal muscular atrophy | ||
| 20.03. | FDA approves new treatment for paediatric patients with any strain of Hepatitis C | ||
| 20.03. | Roche to begin Actemra/RoActemra trial with COVID-19 pneumonia patients | ||
| 19.03. | Pfizer's abrocitinib meets co-primary efficacy endpoints in phase 3 AD trial | ||
| 19.03. | Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran | ||
| 19.03. | Dicerna receives orphan drug designation from FDA for DCR-A1AT to treat alpha-1 antitrypsin deficiency | ||
| 19.03. | Entos to develop Fusogenix DNA vaccine to prevent COVID-19 infections | ||
| 18.03. | Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial | ||
| 18.03. | RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration | ||
| 18.03. | Merck announces top-line results from phase 3 trials evaluating Gefapixant | ||
| 18.03. | Pfizer, BioNTech collaborate to develop vaccine for COVID-19 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
